<DOC>
	<DOC>NCT02749630</DOC>
	<brief_summary>This study is a randomized, observer-blinded, placebo-controlled study to evaluate safety, tolerability, immunogenicity, and pharmacokinetics of repeat dosing of intravenous (IV) UTTR1147A. The study will consist of a repeat dose escalation in healthy volunteers (HV) and a repeat dose escalation in Ulcerative Colitis (UC) patients across multiple sites.</brief_summary>
	<brief_title>A Safety Study of Intravenously Administered UTTR1147A in Healthy Volunteers and Patients With Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis, Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>General inclusion criteria: No history of malignancy and documentation of ageappropriate cancer screening For women of childbearing potential: agreement to remain abstinent or use contraceptive methods For men: agreement to remain abstinent or use contraceptive measures and agreement to refrain from donating sperm For Healthy Volunteers Only: Age 18 50 Body mass index (BMI) between 18 and 32 kg/m2, inclusive In good health with no clinically significant findings from medical history, 12lead electrocardiogram (ECG), and vital signs Normal or not clinically significant laboratory results For Ulcerative Colitis Patients Only: Age 18 80 Eligible to receive biologic therapy Disease duration of &gt; / = 12 weeks Diagnosis of moderate to severe ulcerative colitis General exclusion criteria: History of inflammatory skin disorders History of any cancer History of anaphylaxis, hypersensitivity, or drug allergies History of alcoholism or drug addiction Positive tests indicating infection for hepatitis C, hepatitis B , or HIV Use of a nonbiologic investigational drug or participation in an investigational study with a nonbiologic drug within 30 days prior to study drug administration Use of a biologic investigational therapy or participation in an investigational study involving biologic therapy within 90 days or 5 halflives History or presence of an abnormal ECG that is clinically significant Any acute or chronic condition that would limit the subject's ability to complete and/or participate in this clinical study Pregnant or lactating, or intending to become pregnant for duration of study For HV Only: Known family history of gastrointestinal (GI) and/or colon cancer Prior exposure to UTTR1147A For UC Patients Only: Significant uncontrolled comorbidity, such as neurological, cardiac, pulmonary, renal, hepatic, endocrine, or gastrointestinal (GI) disorders History of Primary Sclerosing Cholangitis Active antiTNF induced psoriasiform or eczematous lesions Moderate to severe anemia Presence of an ileostomy or colostomy Total proctocolectomy Positive screening test for latent mycobacterial tuberculosis infection Impaired renal function Impaired hepatic function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>